Details for New Drug Application (NDA): 017869
✉ Email this page to a colleague
NDA 017869 describes FUNDUSCEIN-25, which is a drug marketed by Novartis and is included in one NDA. Additional details are available on the FUNDUSCEIN-25 profile page.
The generic ingredient in FUNDUSCEIN-25 is fluorescein sodium. There are five drug master file entries for this compound. Four suppliers are listed for this compound. Additional details are available on the fluorescein sodium profile page.
The generic ingredient in FUNDUSCEIN-25 is fluorescein sodium. There are five drug master file entries for this compound. Four suppliers are listed for this compound. Additional details are available on the fluorescein sodium profile page.
Summary for 017869
| Tradename: | FUNDUSCEIN-25 |
| Applicant: | Novartis |
| Ingredient: | fluorescein sodium |
| Patents: | 0 |
Medical Subject Heading (MeSH) Categories for 017869
Profile for product number 001
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | INJECTABLE;INJECTION | Strength | 25% **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | ||||
| Approval Date: | Approved Prior to Jan 1, 1982 | TE: | RLD: | Yes | |||||
Complete Access Available with Subscription
